TY - JOUR
T1 - The natriuretic peptides in cardiovascular medicine
AU - Munagala, Vijaya K.
AU - Burnett, John C.
AU - Redfield, Margaret M.
N1 - Funding Information:
Supported by grants from Biosite, Inc.; San Diego, California and Scios, Inc.; Fremont, California
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2004/12
Y1 - 2004/12
N2 - Within the last five years, assay systems for measurement of plasma levels of brain natriuretic peptide (BNP) have been approved as a diagnostic aid for heart failure (HF). Similarly, nesiritide, a recombinant form of human BNP, has been approved for the treatment of acutely decompensated HF. Both BNP as a diagnostic test and a therapeutic modality are rapidly becoming integrated into clinical practice. The purpose of this review is to provide a brief overview of the physiology of the natriuretic peptides relevant to their informed clinical use. The current literature regarding the utility of measuring BNP for the diagnosis and management of HF is reviewed and practical recommendations regarding the interpretation of BNP levels are offered. The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent.
AB - Within the last five years, assay systems for measurement of plasma levels of brain natriuretic peptide (BNP) have been approved as a diagnostic aid for heart failure (HF). Similarly, nesiritide, a recombinant form of human BNP, has been approved for the treatment of acutely decompensated HF. Both BNP as a diagnostic test and a therapeutic modality are rapidly becoming integrated into clinical practice. The purpose of this review is to provide a brief overview of the physiology of the natriuretic peptides relevant to their informed clinical use. The current literature regarding the utility of measuring BNP for the diagnosis and management of HF is reviewed and practical recommendations regarding the interpretation of BNP levels are offered. The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent.
UR - http://www.scopus.com/inward/record.url?scp=8444220555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8444220555&partnerID=8YFLogxK
U2 - 10.1016/j.cpcardiol.2004.07.002
DO - 10.1016/j.cpcardiol.2004.07.002
M3 - Article
C2 - 15550914
AN - SCOPUS:8444220555
SN - 0146-2806
VL - 29
SP - 707
EP - 769
JO - Current Problems in Cardiology
JF - Current Problems in Cardiology
IS - 12
ER -